Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Caption Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.52M	Buy	+45,000	New	+$4.7M	0.03%	554
2025 Q1	–	Sell	-98,934	Closed	-$4.15M	–	1939
2024 Q4	$3.82M	Buy	98,934 +76,834	+348%	+$3.35M	0.04%	463
2024 Q3	$995K	Buy	+22,100	New	+$893K	0.02%	777
2023 Q3	–	Sell	-19,140	Closed	-$529K	–	1494
2023 Q2	$529K	Buy	19,140 +18,897	+7,777%	+$473K	0.01%	810
2023 Q1	$5.59K	Sell	243 -39,757	-99%	-$668K	﹤0.01%	1023
2022 Q4	$436K	Hold	40,000	–	–	0.01%	951
2022 Q3	$337K	Buy	40,000 +29,600	+285%	+$280K	﹤0.01%	1156
2022 Q2	$82K	Sell	10,400 -59,600	-85%	-$721K	﹤0.01%	1312
2022 Q1	$1.66M	Sell	70,000 -122,702	-64%	-$3.46M	0.02%	820
2021 Q4	$6.59M	Buy	192,702 +82,702	+75%	+$2.61M	0.07%	370
2021 Q3	$1.95M	Buy	+110,000	New	+$4.69M	0.02%	769

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Caption Management's PTGX Position: Q2 2026 in Review

Caption Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 45,000 shares worth $5.52M. The stake represents 0.03% of the portfolio and ranks #554 among its holdings. This is a return to the name: Caption Management previously reported a position in PTGX as recently as Q4 2024.

Caption Management first reported a position in PTGX in Q3 2021 and has held it in 11 quarters since. The position peaked at $6.59M in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Caption Management held 45,000 shares of Protagonist Therapeutics worth $5.52M as of Q2 2026.
Protagonist Therapeutics was a new Caption Management position in Q2 2026.
Protagonist Therapeutics made up 0.03% of Caption Management's portfolio in Q2 2026, its #554 holding.
Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 11 quarters since.
Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.